BR112014004560A2 - compostos e composições como inibidores de c-kit quinase - Google Patents
compostos e composições como inibidores de c-kit quinaseInfo
- Publication number
- BR112014004560A2 BR112014004560A2 BR112014004560A BR112014004560A BR112014004560A2 BR 112014004560 A2 BR112014004560 A2 BR 112014004560A2 BR 112014004560 A BR112014004560 A BR 112014004560A BR 112014004560 A BR112014004560 A BR 112014004560A BR 112014004560 A2 BR112014004560 A2 BR 112014004560A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- kinase inhibitors
- compositions
- kit
- pdgfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
resumo patente de invenção: "compostos e composições como inibidores de c-kit quinase". a invenção refere-se a compostos de fórmula (i) e (ii) e a composições farmacêuticas dos mesmos, que são úteis como inibidores de proteína quinase, bem como métodos para usar tais compostos para tratar, melhorar ou prevenir uma condição associada à atividade de quinase anormal ou desregulada. em algumas modalidades, a invenção fornece métodos para usar tais compostos para tratar, melhorar ou prevenir doenças ou distúrbios que envolvem ativação anormal de c-kit ou c-kit e pdgfr (pdgfr?, pdgfr?) quinases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530038P | 2011-09-01 | 2011-09-01 | |
| PCT/US2012/052802 WO2013033167A1 (en) | 2011-09-01 | 2012-08-29 | Compounds and compositions as c-kit kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014004560A2 true BR112014004560A2 (pt) | 2017-04-04 |
Family
ID=46829904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014004560A BR112014004560A2 (pt) | 2011-09-01 | 2012-08-29 | compostos e composições como inibidores de c-kit quinase |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8569283B2 (pt) |
| EP (1) | EP2751104B1 (pt) |
| JP (1) | JP6134319B2 (pt) |
| KR (1) | KR101962495B1 (pt) |
| CN (1) | CN103797011B (pt) |
| AP (1) | AP2014007493A0 (pt) |
| AR (1) | AR087753A1 (pt) |
| AU (1) | AU2012302042B2 (pt) |
| BR (1) | BR112014004560A2 (pt) |
| CA (1) | CA2845169C (pt) |
| CL (1) | CL2014000492A1 (pt) |
| CO (1) | CO6900141A2 (pt) |
| CR (1) | CR20140107A (pt) |
| CU (1) | CU20140024A7 (pt) |
| EA (1) | EA026152B1 (pt) |
| ES (1) | ES2761332T3 (pt) |
| GT (1) | GT201400034A (pt) |
| IL (1) | IL231227A0 (pt) |
| MA (1) | MA35460B1 (pt) |
| MX (1) | MX339937B (pt) |
| PE (1) | PE20140909A1 (pt) |
| PL (1) | PL2751104T3 (pt) |
| PT (1) | PT2751104T (pt) |
| SG (1) | SG2014014369A (pt) |
| TN (1) | TN2014000068A1 (pt) |
| TW (1) | TW201313717A (pt) |
| UY (1) | UY34301A (pt) |
| WO (1) | WO2013033167A1 (pt) |
| ZA (1) | ZA201401175B (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6134319B2 (ja) | 2011-09-01 | 2017-05-24 | ノバルティス アーゲー | ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物 |
| US9199981B2 (en) * | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| DK3007689T3 (en) | 2013-01-10 | 2018-06-14 | Pulmokine Inc | NON-SELECTIVE KINASE INHIBITORS |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| JP6483714B2 (ja) | 2013-10-11 | 2019-03-13 | ローレンス エス． ジスマン， | 噴霧乾燥製剤 |
| US20150288928A1 (en) * | 2014-04-08 | 2015-10-08 | Sony Corporation | Security camera system use of object location tracking data |
| CN105384738B (zh) * | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| AU2016287477B2 (en) | 2015-07-02 | 2021-10-21 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| US10474987B2 (en) * | 2015-08-05 | 2019-11-12 | Whirlpool Corporation | Object recognition system for an appliance and method for managing household inventory of consumables |
| WO2017214413A1 (en) * | 2016-06-08 | 2017-12-14 | Chrysalis, Inc. | Imidazo[1,2-a]pyridine derivatives as histone demethylase inhibitors |
| MA45377A (fr) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Co | Composés hétérocycliques en tant qu'agents antibacteriens |
| MX2018015657A (es) | 2016-06-16 | 2019-03-14 | Janssen Sciences Ireland Unlimited Co | Compuestos heterociclico como antibacterianos. |
| RU2763525C2 (ru) | 2016-10-27 | 2021-12-30 | Пульмокин, Инк. | Комбинированная терапия для лечения легочной гипертензии |
| US20180162291A1 (en) * | 2016-12-12 | 2018-06-14 | Wipro Limited | System and method of dynamically adjusting field of view of an image capturing device |
| MA47676A (fr) | 2017-03-01 | 2021-06-02 | Janssen Sciences Ireland Unlimited Co | Polythérapie |
| MX2020004557A (es) | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Moduladores de la vía de estrés integrada. |
| KR102625224B1 (ko) * | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물 |
| WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| AU2020274564A1 (en) * | 2019-05-13 | 2021-12-09 | Novartis Ag | Crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide |
| KR20220062564A (ko) | 2019-09-13 | 2022-05-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균 화합물 |
| AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022016021A1 (en) | 2020-07-15 | 2022-01-20 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
| WO2022109595A1 (en) * | 2020-11-19 | 2022-05-27 | Third Harmonic Bio, Inc. | Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same |
| WO2022194803A1 (en) | 2021-03-16 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| KR20230158046A (ko) | 2021-03-17 | 2023-11-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항박테리아성 화합물 |
| JP2024509998A (ja) | 2021-03-17 | 2024-03-05 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌化合物 |
| TW202325274A (zh) | 2021-10-28 | 2023-07-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 抗菌化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003251561A1 (en) | 2002-06-20 | 2004-01-06 | Beacon Looms, Inc. | Knitted electrical conductor fabric |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| ES2390227T3 (es) | 2004-09-09 | 2012-11-07 | Natco Pharma Limited | Nuevos derivados de fenilaminopirimidina como inhibidores de la BCR-ABL kinasa |
| WO2006071940A2 (en) | 2004-12-23 | 2006-07-06 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
| US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| EA200970447A1 (ru) * | 2006-11-03 | 2009-10-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| WO2012067965A1 (en) * | 2010-11-15 | 2012-05-24 | Abbott Laboratories | Nampt and rock inhibitors |
| US20130023751A1 (en) | 2011-07-18 | 2013-01-24 | Samuel Victor Lichtenstein | Water retention monitoring |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| JP6134319B2 (ja) | 2011-09-01 | 2017-05-24 | ノバルティス アーゲー | ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物 |
| US20150051206A1 (en) | 2011-09-01 | 2015-02-19 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| EA201490542A1 (ru) | 2011-09-01 | 2014-08-29 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве pdgfr киназных ингибиторов |
-
2012
- 2012-08-29 JP JP2014528537A patent/JP6134319B2/ja active Active
- 2012-08-29 PL PL12756885T patent/PL2751104T3/pl unknown
- 2012-08-29 AP AP2014007493A patent/AP2014007493A0/xx unknown
- 2012-08-29 US US13/598,213 patent/US8569283B2/en active Active
- 2012-08-29 MX MX2014002484A patent/MX339937B/es active IP Right Grant
- 2012-08-29 EA EA201490545A patent/EA026152B1/ru not_active IP Right Cessation
- 2012-08-29 BR BR112014004560A patent/BR112014004560A2/pt not_active Application Discontinuation
- 2012-08-29 CN CN201280042743.4A patent/CN103797011B/zh active Active
- 2012-08-29 SG SG2014014369A patent/SG2014014369A/en unknown
- 2012-08-29 EP EP12756885.5A patent/EP2751104B1/en active Active
- 2012-08-29 WO PCT/US2012/052802 patent/WO2013033167A1/en active Application Filing
- 2012-08-29 CA CA2845169A patent/CA2845169C/en active Active
- 2012-08-29 ES ES12756885T patent/ES2761332T3/es active Active
- 2012-08-29 PE PE2014000295A patent/PE20140909A1/es not_active Application Discontinuation
- 2012-08-29 KR KR1020147008107A patent/KR101962495B1/ko active IP Right Grant
- 2012-08-29 PT PT127568855T patent/PT2751104T/pt unknown
- 2012-08-29 AU AU2012302042A patent/AU2012302042B2/en not_active Ceased
- 2012-08-29 UY UY34301A patent/UY34301A/es not_active Application Discontinuation
- 2012-08-31 AR ARP120103223 patent/AR087753A1/es unknown
- 2012-08-31 TW TW101131942A patent/TW201313717A/zh unknown
-
2013
- 2013-09-19 US US14/031,792 patent/US8754071B2/en active Active
-
2014
- 2014-02-17 ZA ZA2014/01175A patent/ZA201401175B/en unknown
- 2014-02-17 TN TNP2014000068A patent/TN2014000068A1/en unknown
- 2014-02-27 IL IL231227A patent/IL231227A0/en unknown
- 2014-02-27 GT GT201400034A patent/GT201400034A/es unknown
- 2014-02-27 CU CU20140024A patent/CU20140024A7/es unknown
- 2014-02-27 CL CL2014000492A patent/CL2014000492A1/es unknown
- 2014-02-28 CO CO14043417A patent/CO6900141A2/es unknown
- 2014-02-28 CR CR20140107A patent/CR20140107A/es unknown
- 2014-03-28 MA MA36864A patent/MA35460B1/fr unknown
- 2014-04-22 US US14/258,963 patent/US9023839B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014004560A2 (pt) | compostos e composições como inibidores de c-kit quinase | |
| BR112014004319A2 (pt) | compostos e composições como inibidores de c-kit cinase | |
| BR112014004465A2 (pt) | compostos e composições como inibidores de pdgfr cinase | |
| BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
| BR112014003963A2 (pt) | compostos e composições como inibidores de quinase c-kit | |
| MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| NI201100166A (es) | Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa | |
| BR112012022513A2 (pt) | derivados de piperidin-4-il azetidina como inibidores de jak1 | |
| BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
| BR112014030386A2 (pt) | compostos e composições para modular a atividade de egfr | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| BR112013032720A2 (pt) | "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados" | |
| MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
| BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
| UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
| BR112014002675A2 (pt) | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| SV2009003212A (es) | Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct | |
| CO6630193A2 (es) | Inhibidores de la actividad de la proteína tirosina quinasa seleccionada | |
| MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) |
|
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |